




**DECIPHER® ENABLES PERSONALIZED AND ACTIONABLE TREATMENT AFTER SURGERY**



## **Radical prostate surgery?**

The Decipher Prostate Cancer Classifier can help you and your doctor decide on important next steps in your care

**Decipher<sup>®</sup>** is a unique genomic test that assesses your prostate cancer to help you and your doctor personalize your postoperative care

## Understanding your risk

After surgery, many men will be cured but some will have clinical risk factors that indicate they are at risk for their cancer returning\*



In reality, only about 5% of clinically high risk men will experience disease recurrence within 5 years of surgery<sup>1</sup>



**New advances in genomic testing have made it possible to more accurately determine your risk after surgery**

\* According to clinical practice guidelines, men with extra-prostatic disease, seminal vesicle invasion, positive surgical margins or rising PSA are at higher risk of their disease returning.

# Not all prostate cancers are alike

Scientific advances in the field of genomics have made it possible to more accurately determine the aggressiveness of prostate cancer.

No two prostate cancers are alike. The aggressiveness of your prostate cancer is linked to the activity of certain genes in your tumor.

The Decipher test measures the activity of those genes to provide a personalized assessment of your risk after surgery.

Your Decipher risk tells you how likely your cancer is to spread beyond your prostate; it provides information that is distinct from that given by traditional measures such as Gleason score or PSA.

**Decipher adds a unique piece of information to allow you and your doctor to make more informed decisions about your post-operative care**

# **Decipher<sup>®</sup> helps you and your doctor make more informed decisions about your next steps after surgery**

Your doctor uses your surgery specimen and PSA to determine your clinical risk of metastasis, or disease recurrence.




## **Decipher adds new information about the aggressiveness of your cancer by assessing your genomic risk**



- > Provides a more accurate and independent assessment than clinical risk alone



- > Assesses the activity of genes determined to be associated with aggressive prostate cancer



- > Based on the biology of your tumor, predicts your risk of metastasis after surgery

# Know your risk

Your Decipher test result is reported as a probability of metastasis associated with a risk category of low, average or high risk.

- The probability of metastasis is your % genomic risk (out of 100) of the cancer returning within 5 years of surgery. The lower the result, the lower your chances of metastasis
- Based on clinical studies that evaluate patient outcomes, Decipher associates that genomic risk with a risk category:

## Low Risk

98% of men in this category were metastasis free at 5 years. In studies, 60% of clinically high-risk men tested fell into this category<sup>1</sup>



## Average Risk

The average risk of developing metastasis across all high risk men studied

## High Risk


On average, 1 in 5 men in this category experienced metastasis within 5 years of surgery

?






# The lower your Decipher result, the lower your chances of developing metastasis

## Decipher Sample Test Result



In clinical studies of Decipher, 60% of clinically high risk patients tested were genomically low risk and the information provided by Decipher resulted in a 36% change in postoperative treatment<sup>1,2,3</sup>

## Your Decipher risk

-  If your Decipher risk is low, your doctor may decide that you are a good candidate for active monitoring with regular PSA checks. This means your doctor will closely follow you and watch for any changes.
-  If your Decipher risk is average, that means your risk is in line with the average of high risk men tested in clinical studies.
-  If your Decipher risk is high, your doctor may decide that you are an appropriate candidate for additional treatment. The decision to treat is an individual one — your doctor will talk to you about your treatment options.

# Understand your payment options



**GenomeDx offers the Patient Care Program to ensure eligible patients have access to affordable Decipher testing.**

To learn more about the Patient Care Program and Decipher® visit [www.deciphertest.com](http://www.deciphertest.com)

or contact the GenomeDx Patient Care Team today at **1.888.792.1601** (toll free)

## References

1. Karnes, J.R., et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. *Journal of Urology*, 2013.
2. Badani, K. et al. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. *Oncotarget*, 2013.
3. Badani, K. et al. Effect of a genomic classifier test on clinical practice decisions for patients with high risk prostate cancer after surgery. *BJU International*, 2014.

The information contained in this educational guide is provided by GenomeDx Biosciences Inc. and is not intended to be a substitute for information provided by a practicing physician. Talk to your doctor about the information you are considering before you decide on the course of treatment that is best for you.

**Copyright © 2015 GenomeDx Biosciences Inc.**

